Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

etesevimab

- PMLiVE

Eli Lilly’s GIP/GLP-1 receptor agonist tirzepatide shows promise in fatty liver disease MASH

Metabolic dysfunction-associated steatohepatitis is the second most common contributor to liver transplantation in the US

- PMLiVE

Eli Lilly’s Alzheimer’s drug unanimously endorsed by FDA panel of experts

The company is seeking approval of donanemab to treat patients with early stages of the disease

- PMLiVE

Moderna shares positive late-stage results for COVID-19/flu combination vaccine

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

AstraZeneca’s Tagrisso combination receives CHMP recommendation for advanced lung cancer

More than 450,000 people are diagnosed with lung cancer every year in Europe

- PMLiVE

Eli Lilly gains rights to QurAlis’ neurodegenerative disease therapy in deal worth over $620m

The agreement gives the company global rights to QRL-204 and other UNC13A-targeting compounds

EU flag

CHMP recommends Valneva’s chikungunya vaccine for use in adults

If approved, Ixchiq will become the first vaccine available in the EU for the mosquito-borne viral disease

- PMLiVE

WHA announces progress of WHO Member States to conclude pandemic agreement

The agreement is aimed at preventing a repeat of the global health, economic and social impacts of the COVID-19 pandemic

- PMLiVE

Pfizer’s one-time haemophilia B therapy Durveqtix receives CHMP recommendation

More than 38,000 people worldwide are currently affected by the inherited bleeding disorder

- PMLiVE

Takeda’s enzyme replacement therapy recommended by CHMP for rare blood clotting disorder cTTP

If approved, rADAMTS13 will be the first and only enzyme replacement therapy in the EU indicated for cTTP

- PMLiVE

Eli Lilly commits further $6.5m to UNICEF for young people at risk of noncommunicable diseases

The new funding builds on the company’s initial commitment of $14.4m in 2022

- PMLiVE

Eli Lilly to invest additional $5.3bn totalling $9bn in US manufacturing sites

The investment will provide an additional 200 jobs and more than 5,000 construction jobs during development of the site

- PMLiVE

Eli Lilly shares positive late-stage results for mirikizumab in Crohn’s disease

Nearly one in every 100 people in the US are diagnosed with inflammatory bowel disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links